Castle Creek Biosciences

Matthew Gantz, President and CEO

Oct. 14 | 10:30am | BlueRock Therapeutics Ballroom

Exton, PA
(Private)

In-person Presentation
Castle Creek Biosciences is a privately-held, clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options. Castle Creek is using its proprietary autologous fibroblast platform to develop dabocemagene autoficel, an investigational, autologous fibroblast cell-based gene therapy that is designed to be administered intradermally to potentially treat the underlying cause of autosomal recessive and dominant dystrophic epidermolysis bullosa. Castle Creek is also developing FCX-013, an investigational, autologous fibroblast cell-based gene therapy that is designed to be administered intradermally to potentially treat moderate to severe localized scleroderma.
www.castlecreekbio.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions